Jake Checketts

Jake Checketts


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
JCJake Checketts
Jake Checketts
MSMatthew Thomas Sims
Matthew Thomas Sims
MVMatt Vassar
Matt Vassar
Physicians and insurance companies use clinical practice guidelines (CPGs) to make decisions about patient care.1 These guidelines include recommendations derived from a systematic review of research evidence and careful consideration of benefits and harms associated with medical interventions. Ideally, guidelines should be free from biased recommendations and should consider patients’ best interests; however, panels often include physicians with financial ties to pharmaceutical or medical device industries.1 Evidence suggests that physicians receiving industry payments are likely to assess clinical trials more favorably.2 Small payments, such as gifts or meals provided by industry, may even increase the likelihood that physicians will prescribe brand-name drugs.3,4 For these reasons, the Institute of Medicine’s Committee on Conflicts of Interest in Medical Research, Education, and Practice states, “conflicts of interest threaten the integrity of scientific investigations, the objectivity of professional education, the quality of patient care, and the public’s trust in medicine.”5

20 June 2018 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
JCJake Checketts
Jake Checketts
JSJared T. Scott
Jared T. Scott
CMChase Meyer
Chase Meyer
JHJarryd Horn
Jarryd Horn
JJJaclyn Jones
Jaclyn Jones
MVMatt Vassar
Matt Vassar
Background: The fragility index (FI) may prove to be a powerful metric of trial robustness. The FI is the minimum number of patient events that would need to become nonevents in order to nullify a significant result. The fragility quotient (FQ) is the FI divided by the total sample size. This study evaluates the robustness of the 20% of orthopaedic clinical trials that were cited as having strong evidence in the American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines and that could be analyzed with these indices.Methods: From the AAOS recommendations with strong evidence, we extracted the randomized controlled trials that were cited as having supporting evidence that could be analyzed with the FI. Each trial’s FI was calculated using the fragility calculator (www.fragilityindex.com). With use of the Cochrane Risk of Bias Tool 2.0, we evaluated the likelihood of bias. We also performed a post hoc power analysis of eligible studies.Results: The median FI for the 72 trials was 2 events, and the median FQ was 0.022. Of the 72 trials, only 3 (4.2%) were at a low risk of bias, and 35 (48.6%) were at a high risk of bias. Thirty-eight (53%) of the trials were underpowered. We identified a strong correlation between a trial’s FI or FQ and the trial’s power.Conclusions: Our study found that trials that provided strong evidence for orthopaedic surgery guidelines were largely fragile, underpowered, and at risk of bias.

7 February 2018 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
PDF file
JCJake Checketts
Jake Checketts
MSMathew T. Sims
Mathew T. Sims
BDByron Detweiler
Byron Detweiler
KMKevin Middlemist
Kevin Middlemist
JJJaclyn Jones
Jaclyn Jones
MVMatt Vassar
Matt Vassar
Background: The responsibility for ensuring that studies are adequately reported is primarily that of those conducting the study; however, journal policies may influence how thoroughly authors choose to report their research. The use of reporting guidelines and prospective trial registration are promising avenues for ensuring that published studies adhere to the highest methodological standards. The purpose of this study is to evaluate orthopaedic surgery journal policies regarding reporting guidelines and trial registration, and to evaluate the effects that these policies have on adherence to reporting. Methods: We conducted a cross-sectional survey of journal policies and “Instructions for Authors” to determine the journals’ policies and guidance regarding use of reporting guidelines and study registration. We also examined whether trials published in journals referencing CONSORT (Consolidated Standards of Reporting Trials) had higher rates of compliance with publishing a CONSORT flow diagram and whether journals with trial registration policies were more likely to contain registered trials than journals without these requirements. Results: Of the 21 orthopaedic surgery journals, 6 (29%) did not mention a single guideline, and clinical trial registration was required by 11 (52%) orthopaedic surgery journals and recommended by 2 (10%). Of the 21 general medical journals, 3 (14%) did not mention a single guideline, and trial registration was required by 13 (62%) general medical journals and recommended by 5 (24%) others. Furthermore, journals that referenced CONSORT were more likely to publish trials with a CONSORT flow diagram. Journals with trial registration policies were more likely to publish registered trials. Conclusions: Reporting guidelines and trial registration are suboptimally required or recommended by orthopaedic surgery journals. These 2 mechanisms may improve methodology and quality, and should be considered for adoption by journal editors in orthopaedic surgery. Clinical Relevance: Because orthopaedic surgeons rely on high-quality research to direct patient care, measures must be taken to ensure that published research is of the highest quality. The use of reporting guidelines and prospective clinical trial registration may improve the quality of orthopaedic research, thereby improving patient care.

2 August 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
GNGrayson R. Norris
Grayson R. Norris
JCJake Checketts
Jake Checketts
JSJared T. Scott
Jared T. Scott
MVMatt Vassar
Matt Vassar
BNBrent L. Norris
Brent L. Norris
PGPeter V. Giannoudis
Peter V. Giannoudis
The goals for treating fractures around the knee include satisfactory restoration of mechanical alignment, anatomical reduction of the articular surface, and stable fixation to allow early motion of the knee.1 Managing these fractures can be challenging, and adverse outcomes can include nonunion, malunion, heterotopic ossification, arthrofibrosis, compartment syndrome, and infection among others.2

15 September 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
SJSamuel S. Jellison
Samuel S. Jellison
MBMichael Bibens
Michael Bibens
JCJake Checketts
Jake Checketts
MVMatt Vassar
Matt Vassar

17 January 2018 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
JCJake Checketts
Jake Checketts
CCCourtney Cook
Courtney Cook
MVMatt Vassar
Matt Vassar
Background: A long-standing relationship between orthopaedic surgeons and industry has made financial conflicts of interest a concerning issue. Research supports that financial conflicts of interest can influence both medical research and clinical practice. Financial conflicts of interest may also influence clinical practice guideline recommendations and their corresponding appropriate use criteria. Because of the influential nature of these guidelines, it is imperative that care be taken to minimize bias during guideline development. Methods: We retrieved clinical practice guidelines and their corresponding appropriate use criteria from the American Academy of Orthopaedic Surgery that were published or revised between 2013 and 2016. We extracted industry payments received by physicians using the Centers for Medicare & Medicaid Services Open Payments database. We then evaluated the value and types of these payments. We also used these data to determine whether disclosure statements were accurate and whether guideline development was in adherence with the Institute of Medicine’s (IOM’s) standards. Results: Of the 106 physicians that were evaluated, 85 (80%) received at least 1 industry payment, 56 (53%) accepted >$1,000, and 35 (33%) accepted >$10,000. Financial payments amounted to a mean of $93,512 per physician. Total reimbursement for the 85 clinical practice guideline and appropriate use criteria contributors was $9,912,309. We found that disclosure statements disagreed with the Open Payments data and that the IOM standards were not completely enforced. Conclusions: Clinical practice guideline and appropriate use criteria contributors received substantial payments from industry, many disclosure statements were inaccurate, and the IOM standards were not completely met. Clinical Relevance: Clinical practice guidelines and appropriate use criteria are critical for practicing evidence-based medicine. If financial conflicts of interest are present during their development, it is possible that patient care may be compromised.